Cancer Biotherapy: An Introductory Guide

Cancer Biotherapy: An Introductory Guide

by David Kerr (Editor), Annie Young (Editor), Lewis Rowett (Editor)

Synopsis

Recent advances in biology and immunology have opened up new horizons in both our understanding of cancer as a disease, and the potential for cancer therapy. These major developments mean that chemotherapy, radiotherapy and surgery are no longer the only options. Biotherapy, or biological therapy, is now regarded as the fourth treatment modality for patients with cancer. It utilises the great increase in our knowledge of molecular biology, cell biology and immunology to achieve tumour control. New biological agents are currently being used to treat cancer, such as monoclonal antibodies and vaccine therapies to stimulate the body's immune system to attack cancer cells. Biotherapy may be targeted to act specifically on cancer cells. Drugs such as monoclonal antibodies can be designed to recognize and find a particular type of cancer cell, attach itself to them, and destroy them. Naturally occuring biological molecules such as cytokines are also used, and the manipulation of normal biological mechanisms to control or inhibit tumour growth is another key feature of biotherapy. Edited by a team with perspectives in pharmacology, oncology and nursing, and with contributions from experts in the various areas of biotherapy, this book serves as an introduction to the subject. It includes the principles behind biological therapy, with discussion of the impact on the future of the fight against cancer. It has a strong clinical focus, describing the relevant biology and immunology while highlighting clinical relevance and treatment issues.

$93.30

Quantity

10 in stock

More Information

Format: Illustrated
Pages: 336
Edition: Illustrated
Publisher: Oxford University Press, USA
Published: 01 May 2006

ISBN 10: 9780198566
ISBN 13: 9780198566311

Media Reviews
The editors of this new book...provide a good introductory guide to a whole range of biological interventions. The authors do make the very important point that 'individualised' treatment is going to be the order of the day. All cancer are different, we have to find out how different they are with ever-improving laboratory testing, and we have to tailor treatment to suit each cancer's unique profile and bring them back under control biologically. * Oncology News, Vol 1 Issue 5, *
This introductory guide is essential reading as the transition from the laboratory phase to clinical practice is made. Opening chapters on the cell biology of caner and the immune system set the scene, before the clinical development of biological therapies is addressed. The reader is then guided through the various methods and types of biological therapy...The potential of genetic information to benefit patients concludes this guide. [It is] edited by a team with perspectives in pharmacology, oncology and nursing, and [has] contributions from experts in the various areas of biotherapy.
Author Bio
David Kerr is Rhodes Professor of Therapeutics and Clinical Pharmacology at the University of Oxford, and Director of the National Translational Cancer Research Network. He is Editor-in-Chief of OUP's journal Annals of Oncology, and is currently working in Oxford to build a new Institute for Cancer Medicine. He was awarded the CBE in 2002. Lewis Rowett is the Executive Editor of the OUP journal Annals of Oncology, Europe's leading clinical oncology journal. He has worked for the European Society for Medical Oncology since 1998. Annie Young was a biochemist prior to training as a nurse. She was instrumental in starting up a home chemotherapy and gene therapy service in Birmingham, and she is now a Nurse Director covering three counties.